Moreover, the mucosal expression of HAS2 before treatment was inversely correlated with posttreatment serum IFX concentrations from the matched patients with IBD (Figure 2G), suggesting that HA deposition might impair the stability of IFX. This evidence concerns the gene HAS2 and inflammatory bowel disease.